Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27407366 | 0.82 | TDP1 (0.43) | CYP19A1 | |
| SCHEMBL9051041 | 0.81 | SLC6A2 (0.44) | — | |
| SCHEMBL27093592 | 0.78 | TSHR (0.34) | — | |
| SCHEMBL3777319 | 0.74 | GID4 (0.41) | — | |
| SCHEMBL15111039 | 0.73 | SLC6A2 (0.38) | — | |
| Oxazolidine SCHEMBL14720881 | 0.71 | SLC6A2 (0.36) | — | |
| SCHEMBL31016082 | 0.66 | CYP19A1 (0.52) | CYP19A1DDB1CRBN | |
| SCHEMBL3399522 | 0.66 | PRKACA (0.47) | CYP19A1DDB1CRBN | |
| SCHEMBL27653672 | 0.63 | CYP19A1 (0.41) | CYP19A1DDB1CRBN | |
| SCHEMBL22275674 | 0.63 | ESR2 (0.40) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2705028-B1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2019-08-21 | — | — | EP | disclosed |
| US-9556163-B2 | Process for the preparation of a rivaroxaban and intermediates formed in said process | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2017-01-31 | — | — | US | disclosed |
| US-20140142303-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2014-05-22 | — | — | US | disclosed |
| EP-2705028-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | Egis Gyógyszergyár Nyilvánosan Müködö Részvény-Társaság (HU) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012153155-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGIS GYÓGYSZERGYÁR NYILVÃNOSAN MÜKÖDÖ RÉSZVÉNY-TÁRSASÁG (HU) | 2012-11-15 | — | — | WO | disclosed |
| US-7847096-B2 | 4-aminophenylmorpholinone derivatives and their preparation | SALTIGO GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| US-20090018126-A1 | 4-Aminophenylmorpholinone Derivatives and Their Preparation | SALTIGO GMBH (DE) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018126-A1 | 4-Aminophenylmorpholinone Derivatives and Their Preparation | HTR3C, ADRA2C, OPRM1 | CYP19A1 1742/4885DDB1 2837/4885CRBN 921/4885 |
| US-20140142303-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | CYP2C9, CYP3A5, CYP2J2 | CYP19A1 1045/4885DDB1 4720/4885CRBN 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.